Laidlaw downgraded MEI Pharma to Hold from Buy without a price target after the company’s board determined to begin evaluation of strategic alternatives, including potential transactions as well as an orderly wind down of its operation. Given the uncertainty of the company’s future, including a possible total shut down, the firm downgraded the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEIP: